Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Migraine is a disabling primary headache disorder that directly affects more than one billion
people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed …

Background The monoclonal antibody eptinezumab, which targets calcitonin gene-related
peptide, has shown migraine preventive effects starting the day following infusion and …

Migraine is one of the most prevalent and disabling diseases worldwide, but until recently,
few migraine-specific therapies had been developed. Extensive basic and clinical scientific …

Background We compared the tolerability and efficacy of erenumab, a monoclonal antibody
binding to the calcitonin gene-related peptide receptor, to topiramate for migraine …

Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials
(RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness …

Background Several drugs are available for the preventive treatment of both episodic and
chronic migraine. The choice of which therapy to initiate first, second, or third is not …

Introduction Despite advances in the management of headache disorders, some patients
with migraine do not experience adequate pain relief with acute and preventive treatments. It …

Background Clinical trials have shown the safety and clinical superiority of erenumab
compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the …

Objective While there are several trials that support the efficacy of various drugs for migraine
prophylaxis against placebo, there is limited evidence addressing the comparative safety …